Status:
UNKNOWN
Fastigial Nucleus Stimulation for Coronary Heart Disease
Lead Sponsor:
Affiliated Hospital of North Sichuan Medical College
Collaborating Sponsors:
the Third Hospital of Mianyang
Conditions:
Coronary Disease
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
To observe the effects of fastigial nucleus stimulation on serum inflammation, oxidative stress related factors, cardiac autonomic function and prognosis in patients with coronary heart disease
Detailed Description
In recent years, with the improvement of the material living standards of the investigators residents and the change of working lifestyle, the prevalence and mortality of coronary heart disease (CHD) ...
Eligibility Criteria
Inclusion
- Coronary angiography was performed after admission, and coronary heart disease was diagnosed (coronary angiography showed at least one coronary artery with a diameter reduction of ≥50% from more than two different angles)
- Patients and their families agreed and signed informed consent
Exclusion
- Severe chronic heart failure, and LVEF \<30%
- Body temperature \> 38 ° C and / or combined with severe infection in any system
- Severe liver and kidney dysfunction
- Malignant tumor
- Autoimmune diseases
- High blood pressure and diabetes with severe comorbidities
- Use of implantable electronic devices
- Intracranial implanted vascular stents
- Surface treatment electrode conductive materials Allergic or mastoid skin lesions
Key Trial Info
Start Date :
January 16 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2022
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04121715
Start Date
January 16 2019
End Date
January 1 2022
Last Update
October 10 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Third Hospital of Mianyang
Mianyang, Sichuan, China, 0816